Trust Company of Toledo’s Lineage Cell Therapeutics LCTX Stock Holding History

Trust Company of Toledo’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Hold	83,795	–	–	0.01%	366
2026 Q1	$132K	Buy	83,795 +50,000	+148%	+$84.3K	0.01%	325
2025 Q4	$56.4K	Hold	33,795	–	–	0.01%	415
2025 Q3	$57.1K	Hold	33,795	–	–	0.01%	415
2025 Q2	$30.7K	Hold	33,795	–	–	﹤0.01%	475
2025 Q1	$15.3K	Hold	33,795	–	–	﹤0.01%	237
2024 Q4	$17K	Hold	33,795	–	–	﹤0.01%	236
2024 Q3	$30.6K	Hold	33,795	–	–	﹤0.01%	234
2024 Q2	$33.7K	Hold	33,795	–	–	﹤0.01%	230
2024 Q1	$50K	Hold	33,795	–	–	0.01%	224
2023 Q4	$36.8K	Hold	33,795	–	–	0.01%	216
2023 Q3	$39.9K	Sell	33,795 -1,599	-5%	-$2.17K	0.01%	208
2023 Q2	$49.9K	Buy	35,394 +10,394	+42%	+$14.4K	0.01%	200
2023 Q1	$37.5K	Buy	+25,000	New	+$34.9K	0.01%	201

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

RCWM

Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

BWCS

Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Trust Company of Toledo's LCTX Position: Q2 2026 in Review

Trust Company of Toledo held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 83,795 shares worth $110K. The position accounts for 0.01% of the portfolio, ranked #366.

Trust Company of Toledo first reported a position in LCTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $132K in Q1 2026. 32 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Trust Company of Toledo held 83,795 shares of Lineage Cell Therapeutics worth $110K as of Q2 2026.
Trust Company of Toledo left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up 0.01% of Trust Company of Toledo's portfolio in Q2 2026, its #366 holding.
Trust Company of Toledo first reported a position in Lineage Cell Therapeutics in Q1 2023 and has held it in 14 quarters since.
Trust Company of Toledo's Lineage Cell Therapeutics position peaked at $132K in Q1 2026.
32 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Trust Company of Toledo's 13F filing for Q2 2026, filed 16 Jul 2026.